Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05215340
Title Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS

Additional content available in CKB BOOST